Imatinib Mesylate News and Research

RSS
Imatinib mesylate (also called Gleevec® or STI571) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of some forms of adult and pediatric chronic myelogenous leukemia (CML), and for the treatment of a rare form of cancer called gastrointestinal stromal tumor (GIST).

With CML, imatinib works by blocking an abnormal enzyme characteristic of the disease. In GIST, imatinib blocks a different abnormal enzyme found on the tumor cells.

Imatinib is the first approved drug to directly turn off the signal of a protein known to cause a cancer. Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease.

Imatinib is being investigated for its effectiveness against other kinds of cancer, as well, including acute lymphocytic leukemia and hypereosinophilic syndrome (HES).
New compound that is designed to overcome Gleevec resistance

New compound that is designed to overcome Gleevec resistance

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

Mutation of a gene involved in non-small cell lung cancer linked to drug effectiveness

Mutation of a gene involved in non-small cell lung cancer linked to drug effectiveness

St. John’s wort may interfere with cancer-fighting drug’s ability to prevent relapse in leukemia patients

St. John’s wort may interfere with cancer-fighting drug’s ability to prevent relapse in leukemia patients